natgillin/translations-raw huggingface dataset:
In the population pharmacokinetic analysis, gender was found to be a covariate which explains some of the inter-patient variability, with a 22% greater steady state clearance (CLss) and a 19% greater volume of distribution (V) in males.
V analizi populacijske farmakokinetike se je spol izkazal kot sospremenljivka, ki pojasni del variabilnosti med bolniki: pri moških je očistek v stanju dinamičnega ravnovesja (CLss) za 22 % večji, volumen porazdelitve (V) pa za 19 % večji.
In the Portrazza+GC arm, 51 % of patients continued with single-agent Portrazza after completing chemotherapy.
V skupini Portrazza+GC je 51 % bolnikov nadaljevalo zdravljenje z zdravilom Portrazza v monoterapiji po zaključeni kemoterapiji.
In the post marketing setting, cases of leukemia have been reported in patients treated with a TNF-antagonist.
Med obdobjem trženja so bili opisani primeri levkemije pri bolnikih, zdravljenih z antagonistom TNF.
In the post- marketing period rare cases of liver cirrhosis and liver failure have been reported.
V obdobju trženja so poročali o redkih primerih jetrne ciroze in jetrne odpovedi.
In the post- marketing setting, isolated reports of transient, spontaneously resolving complete AV block have been observed during the six hour monitoring period following the first dose of Gilenya.
Posamezna poročila po prihodu zdravila na trg opisujejo pojavljanje prehodnega kompletnega atrioventrikularnega bloka, ki je spontano izzvenel in do katerega je prišlo v obdobju 6-urnega opazovanja bolnika po prejemu prvega odmerka zdravila Gilenya.
In the post- marketing setting, serious cases of keratitis and ulcerative keratitis have been rarely reported (see section 4.4).
Med uporabo v obdobju trženja so bili redko poročani resni primeri keratitisa in ulcerativnega keratitisa (glejte poglavje 4.4).
In the post-hoc immunogenicity analysis of data from TKT024/024EXT studies, 51% (32/63) patients treated with 0.5mg/kg weekly idursulfase had at least 1 blood sample that tested positive for anti- idursulfase antibodies, and 37 % (23/63) tested positive for antibodies on at least 3 consecutive study visits.
V post hoc analizi imunogenosti na podlagi podatkov iz študij TKT024/024EXT je imelo 51 % (32/63) bolnikov, zdravljenih z 0,5 mg/kg idursulfaze na teden, vsaj 1 krvni vzorec, ki je bil pozitiven za protitelesa proti idursulfazi, 37 % (23/63) pa je bilo pozitivnih za protitelesa pri vsaj 3 zaporednih obiskih v študiji.
In the post-marketing experience rare cases of sudden death have been reported in patients affected by Prader-Willi syndrome treated with somatropin, although no causal relationship has been demonstrated.
Iz izkušenj v obdobju trženja so poročali o redkih primerih nenadne smrti pri bolnikih z Prader- Willijevim sindromom, zdravljenih s somatropinom, čeprav vzročne povezave niso potrdili.
In the post-marketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other central nervous system (CNS) depressant medicinal products.
V obdobju trženja so poročali o primerih odpovedi pljuč in kome pri bolnikih, ki so jemali pregabalin in druga zdravila, ki zavirajo osrednji živčni sistem.
In the post-marketing period there have been rare reports of pulmonary oedema in patients treated with STAYVEER who had a suspected diagnosis of pulmonary veno-occlusive disease.
V obdobju po uvedbi zdravila na trg so pri bolnikih, zdravljenih z zdravilom STAYVEER, pri katerih so sumili na pljučno venookluzivno bolezen, o pljučnem edemu poročali redko.
In the post-marketing period, cases of elevated blood pressure, including rare cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline.
V obdobju trženja so pri bolnikih, ki so jemali razagilin, poročali o primerih zvišanega krvnega tlaka, vključno z redkimi primeri o hipertenzivni krizi, povezani z zaužitjem neznane količine s tiraminom bogatih jedi.
In the post-marketing setting cutaneous vasculitis has been reported in patients treated with filgrastim.
Pri bolnikih, zdravljenih s filgrastimom, so v obdobju trženja poročali o pojavu kožnega vaskulitisa.
In the post-marketing setting, cases of foetal renal growth and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women receiving Herceptin.
V obdobju po prihodu zdravila na trg so pri nosečnicah, ki so prejemale zdravilo Herceptin, poročali o primerih motenj v rasti plodovih ledvic in/ali njihovem delovanju, v povezavi z oligohidramnijem, od katerih so bili nekateri povezani s smrtno hipoplazijo pljuč pri plodu.
In the post-marketing setting, cases of infections with opportunistic pathogens, such as viral (e.g. varicella zoster virus [VZV], John Cunningham virus [JCV] causing Progressive Multifocal Leukoencephalopathy, herpes simplex virus [HSV]), fungal (e.g. cryptococci including cryptococcal meningitis) or bacterial (e.g. atypical mycobacterium), have been reported (see section 4.4).
V okviru uporabe zdravila po njegovem prihodu na trg so poročali o primerih okužb z oportunističnimi patogeni, kot so virusne okužbe (na primer z virusom noric, virusom John Cunningham [virusom JC], ki povzroča progresivno multifokalno levkoencefalopatijo, virusom herpes simpleks), glivične okužbe (na primer s kriptokoki, vključno s kriptokoknim meningitisom) ali bakterijske okužbe (na primer z atipično mikobakterijo) (glejte poglavje 4.4).
In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
Pri spremljanju zdravila v obdobju trženja so poročali o primerih levkemije pri bolnikih zdravljenjih z antagonisti TNF.
In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
Pri spremljanju zdravila v obdobju trženja so poročali o primerih levkemije pri bolnikih, zdravljenih z antagonisti TNFα.
In the post-marketing setting, cases of leukaemia have been reported in patients treated with a TNF-antagonist.
V spremljanju v obdobju trženja so poročali o primerih levkemije pri bolnikih zdravljenjih z antagonisti TNF.
In the post-marketing setting, events of hypersensitivity, including rare events of anaphylactic reactions, have been reported in patients receiving XGEVA.
V obdobju trženja zdravila so pri bolnikih, ki prejemajo zdravilo XGEVA, poročali o primerih preobčutljivosti, vključno z redkimi primeri anafilaktičnih reakcij.
In the post-marketing setting, isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (see section 4.4).
V obdobju trženja so poročali o posameznih primerih srpastoceličnih kriz pri bolnikih z genetsko predispozicijo za srpaste celice ali z anemijo srpastih celic (glejte poglavje 4.4).
In the post-marketing setting, isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (see section 4.4).
V obdobju trženja so pri bolnikih s srpastocelično zasnovo ali srpastocelično anemijo poročali o posameznih primerih srpastoceličnih kriz (glejte poglavje 4.4).
In the post-marketing setting, isolated cases of sickle cell crises have been reported in patients with sickle cell trait or sickle cell disease (see section 4.4).
V obdobju trženja so pri prenašalcih srpastocelične anemije in bolnikih s srpastocelično anemijo poročali o posameznih primerih srpastoceličnih kriz (glejte poglavje 4.4).
In the post-marketing setting, serious infusion-related reactions have been reported, including rare post-marketing reports with a fatal outcome.
Med uporabo v obdobju trženja so bile opisane tudi resne z infundiranjem povezane reakcije, vključno z redkimi primeri s smrtnim izidom.
In the post-marketing setting, severe symptomatic hypocalcaemia has been reported (see section 4.8), with most cases occurring in the first weeks of initiating therapy, but it can occur later.
V obdobju trženja zdravila so poročali o hudi simptomatski hipokalciemiji (glejte poglavje 4.8), večina primerov se je pojavila v prvih tednih po uvedbi zdravljenja, a pojavi se lahko tudi pozneje.
In the postmarketing experience there have been reports of restlessness, bleeding into the chest, excessive sweating, pain and redness at the injection site, increased body temperature, and increased need for catecholamines (medicine to elevate blood pressure) in the course of the treatment.
V času trženja zdravila so v poteku zdravljenja poročali o nemiru, krvavitvah v prsno votlino, prekomernem potenju, bolečinah in pordelosti na mestu injiciranja, zvišani telesni temperaturi in povečani potrebi po kateholaminih (zdravila za zvišanje krvnega tlaka).
In the postmarketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other central nervous system (CNS) depressant medicinal products.
V obdobju trženja so poročali o primerih respiratorne insuficience in kome pri bolnikih, ki so jemali pregabalin in druga zdravila, ki zavirajo osrednji živčni sistem.
In the postmarketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant medicinal products.
V obdobju trženja so poročali o primerih odpovedi pljuč in kome pri bolnikih, ki so jemali pregabalin in druga zdravila, ki zavirajo osrednji živčni sistem.
In the postmarketing setting five cases of MabThera overdose have been reported.
Po prihodu zdravila na trg je bilo opisanih pet primerov prevelikega odmerjanja zdravila MabThera.
in the powder: mannitol and human albumin, in the solvent (sodium chloride solution 5.4 mg/ml (0.54% w/v)): sodium chloride, water for injection.
v prašku: manitol in humani albumin, v vehiklu (raztopina natrijevega klorida 5,4 mg/ml (0,54 % m/v)): natrijev klorid, voda za injekcije.
in the powder: mannitol and human albumin. in the solvent: sodium chloride, water for injection.
v prašku: manitol in humani albumin v vehiklu: natrijev klorid, voda za injekcije.
In the powder: poly (D,L-lactide-co-glycolide) and sucrose.
V prašku: poli (D,L-laktid koglikolid) in saharoza.
In the powder: sucrose and trometamol
V prašku: saharoza in trometamol
In the PPE population of women vaccinated with Gardasil in the base study, no cases of HPV diseases (HPV types 6/11/16/18 related high grade CIN) were observed up to approximately 10 years.
V PPE populaciji v obdobju do približno 10 let niso odkrili primerov bolezni zaradi HPV (s HPV tipi 6/11/16/18 povezana CIN visoke stopnje).
In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related CIN any grade and Genital Warts) were observed through 8.4 years (median follow-up of 7.2 years).
V PPE populaciji v obdobju 8,4 leta (mediani čas spremljanja 7,2 leta) niso odkrili primerov bolezni zaradi HPV (s HPV tipi 6/11/16/18 povezana CIN katere koli stopnje in bradavice na spolovilih).
In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related External Genital Lesions) were observed through 10.6 years (median follow- up of 9.9 years).
V PPE populaciji v obdobju 10,6 leta (mediani čas spremljanja 9,9 leta) niso odkrili primerov bolezni zaradi HPV (s HPV tipi 6/11/16/18 povezane lezije na zunanjih spolovilih).
In the PPE population, no cases of HPV diseases (HPV types 6/11/16/18 related high grade CIN) were observed up to approximately 10 years.
V PPE populaciji v obdobju do približno 10 let niso odkrili primerov bolezni zaradi HPV (s HPV tipi 6/11/16/18 povezana CIN visoke stopnje).
In the PPE population, no cases of HPV types 6/11 related genital warts, HPV 6/11/16/18 external genital lesions or HPV 6/11/16/18 high grade AIN in MSM were observed through 9.6 years (median follow-up of 8.5 years).
V PPE populaciji v obdobju 9,6 leta (mediani čas spremljanja 8,5 leta) niso odkrili primerov s HPV tipoma 6/11 povezanih bradavic na spolovilih, s HPV 6/11/16/18 povezanih lezij na zunanjih spolovilih ali s HPV 6/11/16/18 povezanih AIN visoke stopnje pri MSM.
In the PPE population, the efficacy of qHPV vaccine against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 88.7% (95% CI: 78.1, 94.8).
V populaciji PPE je bila učinkovitost qHPV cepiva proti kombinirani pojavnosti s HPV 6, 11, 16 ali 18 povezane persistentne okužbe, genitalnih bradavic, sprememb na vulvi in nožnici, CIN katere koli stopnje, AIS in raka na materničnem vratu 88,7 % (95 % IZ: 78,1; 94,8).
In the pramipexole group, patients received 0,375 mg in the first week, 0.75 mg in the second week and were titrated further in weekly increments of 0.75 mg to their optimal dose up to a maximum of 4.5 mg/day.
V skupini, ki je prejemala pramipeksol, so bolniki prvi teden prejemali 0,375 mg, drugi teden 0,75 mg, nato pa so odmerek postopno povečevali v tedenskih korakih po 0,75 mg do optimalnega odmerka največ
In the pre- and post- natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.
V pre- in postnatalnih študijah na podganah so pri odmerkih, ki so bili toksični za samice, opazili zmanjšano sposobnost preživetja plodov.
In the pre- and post-natal development study in rats, there were no undesirable effects on pregnancy, parturition or lactation of F0 female rats at maternally non-toxic doses (10 and
Pri študijah prenatalnega in postnatalnega razvoja pri podganah niso zasledili neželenih vplivov na brejost, porod ali dojenje F0 samic pri odmerkih, ki niso bili toksični za matere (10 in 20 mg/kg/dan).
In the pre- and post-natal study, an increase in foetal mortality was observed at doses that were toxic to the dams (a dose corresponding to a plasma exposure level 4-fold higher than observed in patients).
Raziskava o obdobju pred porodom in po njem je odkrila povečano umrljivost plodov po odmerkih, ki so bili toksični za samice (odmerkih, pri katerih je izpostavljenost zdravilu v plazmi 4-krat večja kot pri bolnikih).
In the pre- and post-natal study, an increase in foetal mortality was observed at doses that were toxic to the dams (a dose corresponding to a plasma exposure level 4-fold higher than observed in patients).
Raziskava o obdobju pred porodom in po njem je odkrila povečano umrljivost plodov po odmerkih, ki so bili toksični za samice (po odmerkih, pri katerih je izpostavljenost zdravilu v plazmi 4-krat večja kot pri bolnikih).
In the pre-antiviral treatment phase, subjects received open-label eltrombopag to increase the platelet count to ≥ 90,000/µl for ENABLE 1 and ≥ 100,000/µl for ENABLE 2.
V prvi fazi brez protivirusnega zdravljenja so bolniki odprto prejemali eltrombopag za povečanje števila trombocitov do ≥ 90.000/µl pri ENABLE 1 in do ≥ 100.000/µl pri ENABLE 2.
In the pre-specified ITT NIS-LL Responder analysis, patients who discontinued prior to the 18-month time point due to liver transplantation were categorized as non-responders.
Pri predhodno določeni analizi ITT NIS-LL odzivnih bolnikov so bili kot neodzivni bolniki opredeljeni tisti bolniki, ki so zaradi presaditve jeter z zdravljenjem prenehali pred zaključkom 18-mesečnega časovnega obdobja.
In the predefined stratum comparing fondaparinux to placebo (i.e patients treated with non- fibrin specific lytics (77.3%), no reperfusion (22%), fibrin-specific lytics (0.3%), primary PCI (0.4%)), the incidence of death/re-MI at Day 30 was significantly reduced from 14.0% on placebo to 11.3% (hazard ratio 0.80, 95% CI, 0.69, 0.93, p = 0.003).
Pri v naprej določenih skupinah pri katerih so fondaparinuks primerjali s placebom (to je bolniki, ki so se zdravili s fibrinsko nespecifičnimi litiki (77,3%), brez reperfuzije (22 %), fibrinsko specifičnimi litiki (0,3 %) primarno PCI (0,4 %)) se je smrtnost/pojavnost re-MI do 30. dne pomembno zmanjšala s 14,0 % pri placebu na 11,3 % (razmerje tveganja 0,80, 95 % interval zaupanja, 0,69;0,93, p = 0,003).
In the predefined stratum comparing fondaparinux to placebo (i.e patients treated with non- fibrin specific lytics (77.3%), no reperfusion (22%), fibrin-specific lytics (0.3%), primary PCI (0.4%), the incidence of death/re-MI at Day 30 was significantly reduced from 14.0% on placebo to 11.3% (hazard ratio 0.80, 95% CI, 0.69, 0.93, p = 0.003).
Pri v naprej določenih skupinah pri katerih so fondaparinuks primerjali s placebom (to je bolniki, ki so se zdravili s fibrinsko nespecifičnimi litiki (77,3%), brez reperfuzije (22 %), fibrinsko specifičnimi litiki (0,3 %) primarno PCI (0,4 %)) se je smrtnost/pojavnost re-MI do 30. dne pomembno zmanjšala s 14,0 % pri placebu na 11,3 % (razmerje tveganja 0,80, 95 % interval zaupanja, 0,69;0,93, p = 0,003).
In the pregnant rat the AUC for calculated free active substance at this dose was approximately 18 times the human AUC at a 20 mg dose.
Pri breji podgani je bila AUC za izračunano prosto zdravilno učinkovino pri tem odmerku približno 18-kratna AUC človeka pri 20 mg odmerku.
In the pregnant rat, the transfer of 35S-enoxaparin across the maternal placenta to the foetus is minimal.
Pri brejih podganah 35S-enoksaparin le minimalno prehaja skozi placento do ploda.
In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo.
V preskušanju PreSAP je bilo relativno tveganje za isti sestavljeni opazovani dogodek (presojeno) pri celekoksibu 400 mg enkrat na dan v primerjavi s placebom 1,2 (95 % IZ: 0,6–2,4).
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong CYP3A4 inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
V prisotnosti 400 mg/100 mg lopinavirja/ritonavirja dvakrat na dan, močnega zaviralca CYP3A4, se je izpostavljenost seleksipagu povečala za približno 2-krat, medtem ko se izpostavljenost aktivnemu presnovku seleksipaga ni spremenila.
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong OATP (OATP1B1 and OATP1B3) and P-gp inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
V prisotnosti 400 mg/100 mg lopinavirja/ritonavirja dvakrat na dan, močnega zaviralca OATP (OATP1B1 in OATP1B3) in P-gp, se je izpostavljenost seleksipagu povečala za približno 2-krat, medtem ko se izpostavljenost aktivnemu presnovku seleksipaga ni spremenila.
In the presence of an inhibitor, higher doses or appropriate specific treatment may be required.
V prisotnosti inhibitorja so potrebni večji odmerki ali ustrezno specifično zdravljenje.
In the presence of bacterial urease the ratio of the 13C/12C-carbon isotopes is significantly changed.
V prisotnosti bakterijske ureaze se razmerje med 13C in 12C-ogljikovimi izotopi znatno spremeni.
In the presence of clinical manifestations of CHF, discontinuation of sunitinib is recommended.
Če se pojavijo klinični znaki kongestivnega srčnega popuščanja, je priporočljivo prekiniti zdravljenje s sunitinibom.
In the presence of coagulopathy, the oral administration of the chelating agent Dimercaptosuccinic Acid Succimer (DCI) 10 mg/kg or 350 mg/m2 every 8 hours during 5 days and then every 12 hours during 2 weeks is recommended.
Pri koagulopatiji priporočamo peroralno uporabo sredstva za kelacijo sukcimera dimerkaptosukcinske kisline (DCI – »dimercaptosuccinic acid succimer«) v odmerkih po 10 mg/kg ali 350 mg/m2 vsakih 8 ur prvih 5 dni in nato naslednja dva tedna vsakih 12 ur.
In the presence of dasabuvir, paritaprevir exposures increased by 50% to 65% while there was no change in ombitasvir exposures.
V prisotnosti dasabuvirja se je izpostavljenost paritaprevirju povečala za 50 do 65 %, izpostavljenost ombitasvirju pa se ni spremenila.
In the presence of documented resistance that includes Q148 + 2 secondary mutations from G140A/C/S, E138A/K/T, L74I, modelling suggests that an increased dose may be considered for patients with limited treatment options (less than 2 active agents) due to advanced multi class resistance (see section 5.2).
V primeru dokumentirane odpornosti, ki vključuje Q148 +  2 sekundarni mutaciji G140A/C/S, E138A/K/T, L74I, modeliranje kaže, da je mogoče razmisliti o povečanju odmerka pri bolnikih z omejenimi možnostmi zdravljenja (manj kot 2 aktivni učinkovini) zaradi napredovale odpornosti proti več skupinam (glejte poglavje 5.2).
In the presence of fesoterodine there are no changes in the plasma concentrations of combined oral contraceptives containing ethinylestradiol and levonorgestrel.
V prisotnosti fesoterodina ni sprememb plazemskih koncentracij kombiniranih peroralnih kontraceptivov, ki vsebujejo etinilestradiol in levonorgestrel.
In the presence of Helicobacter pylori the 13C-urea is metabolised by the enzyme urease of Helicobacter pylori.
V prisotnosti bakterije Helicobacter pylori se 13C-sečnina presnovi z ureazo bakterije Helicobacter pylori.
In the presence of hypertension or existing cardiovascular, cerebrovascular or peripheral vascular diseases, the weekly increase in Hb and the target Hb should be determined individually taking into account the clinical picture.
Bolnikom z visokim krvnim tlakom ali srčnožilnimi boleznimi, boleznimi možganskih ali perifernih žil moramo tedensko povečanje koncentracije hemoglobina in njegovo ciljno koncentracijo določati individualno in upoštevati klinično sliko
In the presence of hypertension or existing cardiovascular, cerebrovascular or peripheral vascular diseases, the weekly increase in Hb and the target Hb should be determined individually taking into account the clinical picture.
Bolnikom z visokim krvnim tlakom ali srčnožilnimi boleznimi, boleznimi možganskih ali perifernih žil moramo tedensko povečanje koncentracije hemoglobina in njegovo ciljno vrednost določati individualno in upoštevati klinično sliko.
in the presence of immune deficiencies Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics may be administered but a protective immune response may not be elicited.
v prisotnosti imunske pomanjkljivosti se cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics lahko daje, vendar ni nujno, da bo doseţen zaščitni imunski odziv.
In the presence of integrase class resistance this combination should be avoided (see section 4.4).
Ob prisotni odpornosti na zdravila iz skupine zaviralcev integraze se je treba tej kombinaciji izogibati (glejte poglavje 4.4)
In the presence of integrase class resistance this combination should be avoided (see section 4.4).
Pri prisotni odpornosti na zdravila iz skupine zaviralcev integraze se je treba tej kombinaciji izogniti (glejte poglavje 4.4)
In the presence of integrase class resistance, Tivicay should preferably be taken with food to enhance exposure (particularly in patients with Q148 mutations) (see section 5.2).
Pri prisotni odpornosti na zdravila iz skupine zaviralcev integraze se priporoča jemanje zdravila Tivicay med jedjo, da se poveča izpostavljenost (zlasti pri bolnikih z mutacijami Q148) (glejte poglavje 5.2).
In the presence of integrase inhibitor resistance, there are insufficient data to recommend a dose for Tivicay in children and adolescents.
Ni dovolj podatkov, da bi lahko priporočali odmerjanje zdravila Tivicay pri otrocih in mladostnikih v primeru odpornosti na zaviralce integraze.
In the presence of LVDr mutations, combination use of entecavir plus a second antiviral agent (which does not share cross-resistance with either lamivudine or entecavir) should be considered in preference to entecavir monotherapy (see section 4.4.).
V prisotnosti mutacij LVDr je treba razmisliti o kombiniranem zdravljenju z entekavirjem in drugim protivirusnim zdravilom (ki si ne deli navzkrižne odpornosti ne z lamivudinom ne z entekavirjem) in takšnemu zdravljenju dati prednost pred monoterapijo z entekavirjem (glejte poglavje 4.4).
In the presence of myelosuppression or its complications, treatment with Dacogen may be interrupted and/or supportive measures instituted (see sections 4.2 and 4.8).
Če pride do mielosupresije oziroma zapletov, povezanih z njo, je mogoče zdravljenje z zdravilom Dacogen prekiniti in/ali uvesti podporno zdravljenje (glejte poglavji 4.2 in 4.8).